Tag: Absorb

TCT 2017: Advances in device technology needed to improve outcomes with...

Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott) is substantially reduced when the device is...

“Low commercial sales” prompt Abbott to pull the plug on selling...

Abbott has announced that it is to stop selling its first-generation bioresorbable vascular scaffold (Absorb, Abbott Vascular) because of poor sales. The announcement follows...

EuroPCR 2017: Study finds no association between implantation technique and risk...

A study—AIDA (Amsterdam investigator-initiated Absorb strategy all-comers trial)—presented at EuroPCR  (16–19 May, Paris, France) and published in The New England Journal of Medicine has...

EuroPCR 2017: ABSORB China and ABSORB show both comparable safety and...

Data presented from ABSORB China and ABSORB Japan at EuroPCR (16–19 May, Paris, France) show the bioresorbable scaffold Absorb (Abbott Vascular) to have comparable...

Absorb GTS to be restricted to registry use only in Europe

Abbott Vascular has written a letter to European physicians to say that from 31 May, its bioresorbable vascular scaffold (Absorb) will only be available...

The use of bioresorbable scaffold in clinical practice

At JIM 2017 (9-11 February, Milan, Italy), we spoke to Bernardo Cortese (Interventional Cardiology, A.O. Fatebenefratelli, Milano, Italy) about how he uses bioresorbable scaffolds...

ACC 2017: Two-year rate of target lesion failure significantly higher with...

Two-year data from the ABSORB III study indicate that a bioresorbable vascular scaffold (Absorb, Abbott Vascular) is associated with a significantly higher rate of...

The implications of ABSORB II three-year results for the future of...

The idea of a fully bioresorbable scaffold is attractive as the need for mechanical support for the healing artery after percutaneous coronary intervention (PCI)...

TCT 2016: Three-year data fail to show Absorb to be superior...

According to the three-year results of the ABSORB II trial, a bioresorbable vascular scaffold (Absorb, Abbott Vascular) does not provide superior vasomotor reactivity than...

TCT 2016: Late-breakers and first report investigations announced

The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the 2016 Transcatheter...

Absorb now available in the USA following FDA approval

Five years after receiving the CE mark, Abbott Vascular’s bioresorbable vascular scaffold (Absorb) has been granted FDA approval—making it the first fully dissolving scaffold...

Risk of device thrombosis may be significantly higher with Absorb than...

A network meta-analysis, published in JACC: Cardiovascular Interventions, indicates that three contemporary drug-eluting stents—Xience (a cobalt-chromium everolimus-eluting stent; Abbott Vascular), Promus (a platinum-chromium everolimus-eluting...